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z.2012.12Abstract Background: Hypertension is a cardiovascular disease that is affected by environmental,
demographic and genetic factors.
Objective: This study aims to determine the frequency of the CYP2D6*1, *3, *4 and *5 variants
among hypertensive cases and cases with obesity and cases with cardiac complications.
Subjects and methods: DNA was isolated from peripheral blood samples that were collected from
123 hypertensive cases and from 429 healthy non-related controls by using the Magna pure system.
Genomic DNA was used to determine the frequency of CYP2D6*1, CYP2D6*3, CYP2D6*4 and
CYP2D6*5 allelic variants by the application of the light cycler polymerase chain reaction (Real-
time PCR) technique.
Results: Comparing cases of hypertension and controls as regard to the genotypic allelic variants
of CYP2D6 gene, hypertensive cases showed a signiﬁcantly higher wild genotype 1/1 compared to
controls (85.4% vs. 74.8%, p= 0.01) with a lower frequency of mutant genotype 4/4 (1.6% vs.
8.6%, p= 0.008) This phenomenon was manifested among cases of subgroups with obesity that
had signiﬁcantly lower mutant homozygous forms than obese controls (2.3% vs. 9.5%, p 0.04)
and cases with cardiac complications (88.2% vs. 74.8%, p= 0.01).
Conclusion: CYP2D6 polymorphism is positively associated with hypertensive cardiac complica-
tions as well as hypertensive obese cases.
ª 2013 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V. All rights
reserved..com, ahmedali@qumed.edu.
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.002Introduction
Cardiovascular diseases are complex disorders that are af-
fected by environmental, demographic and genetic factors. It
is evaluated that the genetic element associated with blood
pressure variation ranges from 30% to 50% (Tanira, 2005).
Evidence from animal models and human studies suggests that
cytochrome P450 plays a mechanistic role in the development
of hypertension. However, the human cytochrome P450 (CYP)
– containing more than 59 functional genes and 58 pseudo-
genes – are playing an important or dominant role in theand hosting by Elsevier B.V. All rights reserved.
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drugs, and other xenobiotics (Zhou et al., 2009; Bradford,
2002). One of the most important polymorphic P450 genes is
CYP2D6, the debrisoquine hydroxylase. (Bertilsson, 1995;
Sistonen et al., 2007). Although this CYP2D6 makes up only
1.5% of the total cytochrome P450 isoforms, it metabolizes
up to one-quarter of all prescribed drugs such as antidepres-
sant, antipsychotic, antiarrhythmic, opiates and antihyperten-
sive drugs (Murphy et al., 2001).
The CYP2D6 gene is localized on chromosome 22q13
(Heim and Meyer, 1990). It is highly polymorphic variant,
more than 120 alleles had been. These alleles are resulting from
point mutations, rearrangements, additions, deletions and
duplications (Ma et al., 2002; Evans & Relling, 2004). Among
the common allelic variants, individuals with two functional
alleles (wild-type allele, CYP2D6*1), and with one functional
allele are considered extensive metabolizers (EMs) (Gardiner
& Zanger et al., 2001; Gardiner and Begg, 2006). In addition,
individuals with whole gene deletion (null allele) are considered
poor metabolizers (PM) e.g. CYP2D6*5. There are also indi-
viduals with inactivating alleles produced from single nucleo-
tide polymorphisms alone or in combination, deletion or
insertion of a single or multiple base(s), e.g. CYP2D6*3 and
CYP2D6*4 are considered PM (Linder et al., 1997; Sachse et
al., 1997; Bradford, 2002; Kirchheiner et al., 2001; Zanger et
al., 2004; Guzey and Spigset, 2004). Published studies have
determined that the frequency of the alternative CYP2D6 phe-
notypes varies signiﬁcantly among different racial/ethnic
groups. Genetic variation of drug metabolizing enzymes also
has been shown as one of the major causes of the inter-individ-
ual variability to drug response. Therefore the impact of
CYP2D6 polymorphism on the clearance of or response to a
series of cardiovascular drugs was addressed (Zhou, 2009).
Although the frequencies of CYP2D6 mutant alleles have
been studied extensively in different populations, limited infor-
mation is available for those of the Middle East populations.
The objective of the current study was to determine the fre-
quencies of the CYP2D6*1, *3, *4 and *5 variants among
Egyptian hypertensive cases and with complicated subgroups
comparing with healthy individuals.
Subjects and methods
As a pilot study ahead of a future wide scale genetic analysis of
hypertensive cases, a convenient sample of 123 cases (83 males
and 40 females) with an age mean ± SD of 50.93 ± 15.43 was
selected for the study. Of these cases, 22.8.3% had a positive
family history of hypertension, 28.5% had a positive parental
consanguinity, 10.6% were smokers, 71.5% were obese and
39% had type 2 diabetes. For comparison, 429 normal healthy
unrelated subjects (227 males and 202 females) with an age
mean and SD of 47.65 ± 11.15 years were taken from the
same locality as controls.
Cases were furthermore stratiﬁed according to the associa-
tion of other complications into 4 subgroups including: Gp I:
Hypertension with obesity 88 (71.5%), Gp II: Hypertension
with diabetes 48 (39%), Gp III: Hypertension with cardiac
complication 76 (61.8%) and Gp IV: Hypertension with renal
complication 22 (17.9%).
Obesity was diagnosed on the basis of the deﬁnitions estab-
lished by the World Health Organization (WHO) in 1997 and
published in 2000, that deﬁnes the body mass index (BMI) ofobesity as being 30 or greater (WHO, 2012). On the other
hand, type 2 diabetes was diagnosed on the basis of blood su-
gar during fasting time (12–14 h), being higher than 126 mg/dL
at least for two times; or with symptoms of hyperglycemia plus
a random plasma glucose being higher than 200 mg/dl
(11.1 mmol/l) (American Diabetes Association, 2009). The
other cases with cardiac and renal complications were diag-
nosed by renal and cardiology departments.DNA extraction and ampliﬁcation
Genomic DNA was isolated from collected peripheral blood
samples using MagNA Pure LC instrument (Roche Molecular
Biochemicals, Mannheim, Germany), according to the manu-
facturer’s standard. Oligonucleotide primers and ﬂuores-
cence-labeled hybridization probes were designed for
ampliﬁcation and sequence-speciﬁc detection of corresponding
polymorphism (TIB MolBiol; Berlin, Germany). During PCR
the amplicon was detected using two speciﬁc hybridization
probes, one labeled with ﬂuorescein and one with LightCycler
Red 640 (LCRed640). The absence of a CYP allele introduces
a destabilizing mismatch, which results in a decreased melting
temperature. For mutation detection with the LightCycler, a
20 ll reaction was performed. The reaction mixture contained:
1 · LightCycler DNA Master Hybridization Mix (Roche),
2.0 mM MgCl2, 5 pmol of each primer, 4 pmol Sensor probe,
8 pmol Anchor probe, and 200 ng genomic DNA. PCR condi-
tions were: 120 s at 95 C for DNA denaturation, 40 cycles (0 s
at 95 C (denaturation), 10 s at 55 C (annealing), 40 s at 72 C
(extension)). Next a melting curve analysis was performed by
heating at 95 C for 60 s, followed by cooling at 40 C for
120 s and gradual heating (0.1 C/s) up to 80 C. After the
melting curve analysis a ﬁnal cooling was performed at 40 C
for 30 s. To analyze the melting curves the corresponding melt-
ing peaks were calculated by plotting the ﬁrst negative deriva-
tive of the ﬂuorescence with respect to the temperature (dF/
dT vs. T) Fig. 1.
Probes used in the RT PCR ‘‘variable base is highlighted in
yellow if the probe is wild type speciﬁc or green for the poly-
morphism speciﬁc probes’’:
Statistical analysis
Statistical analysis was done using the SPSS software program
version 17. Allelic and genotypic frequencies were compared
and statistically analyzed using the Fisher’s exact test and
Odds ratio (OR) with 95% conﬁdence intervals (95% CI).
Conformity of genotype distributions with Hardy–Weinberg
(HW) equilibrium was evaluated by Chi-square analysis. For
all tests, a p-value < 0.05 was considered to be statistically
signiﬁcant.Results
Comparing cases of hypertension and controls as regards the
genotypic allelic variants ofCYP2D6 gene showed a signiﬁcantly
Figure 1 (A) ‘‘Melting peak of CYP2D6 3*5 3/3’’, (B) ‘‘Melting peak of CYP2D6 3*5 5/5’’, (C) ‘‘Melting peak of CYP2D6 3*5 3/5’’.
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controls (85.4% vs. 74.8%, OR 1.96, 95% Cl = 1.1–3.4,
p= 0.01) with a lower frequency of mutant genotypes (1.6%
vs. 8.6%,OR0.2, 95%Cl = 0.04–0.7, p= 0.008) (Table 1). This
phenomenon was manifested among cases of subgroups with
obesity that had signiﬁcantly lower mutant homozygous forms
than obese controls (2.3% vs. 9.5%, OR 0.2, 95% Cl = 0.05–
0.95, p= 0.04) (Table 2) and cases with cardiac complications
(1.3% vs. 8.6%, OR 0.1, 95% Cl = 0.02–1.05, p= 0.03) (Table
3). Other subgroups were neglected because their genotyping
was not conﬁrmed. Regarding the allelic frequency, hypertensive
cases had also a signiﬁcant higher frequency of the wild type allele
1 (91.9% vs. 82.6%, OR 2.3, 95%Cl = 1.4–3.8, p= 0.001) with
a signiﬁcantly lower frequency of the mutant alleles compared to
controls (8.1% vs. 16.9%OR0.4, 95%CI= 0.3–0.7, p= 0.001)
(Table 1).Discussion
Based on the polymorphism detection, the present study iden-
tiﬁed the prevalent wild genotype (CYP2D6 1/1) and the most
common inactive genotypes (mutant or poor metabolic) partic-
ularly CYP2D6 4/4 in hypertensive cases and healthy controls.Table 1 Frequency of genotypic and allelic variants of CYP2D6 ge
CYP2D6 Genotypes
1/1 1/M
n (%) n (%)
Controls n= 429 321 (74.8) 71 (16.6)
Cases n= 123 105 (85.4) 16 (13)
Dominant
1/1 vs.
1/M+M/M#
Additive
1/M vs. 1/1 +M/M
p 0.01* 0.4
OR
(95% CI)
1.96
(1.1–3.4)
0.2
(0.4–1.4)
# M=mutant alleles of CYP2D6 i.e. alleles 3, 4 and 5.
* p signiﬁcant < 0.05.
Table 2 Frequency of genotypic and allelic variants of CYP2D6 ge
CYP2D6 Genotypes
1/1 1/M
n (%) n (%)
Obese controls n= 318 237 (74.5) 51 (16.0)
Obese Complication n= 88 74 (84.1) 12 (13.6)
Dominant 1/1
vs.
1/M+M/M#
Additive
1/M vs.
1/1 +M/M
p 0.07 0.6
OR
(95% CI)
1.8
(0.97–3.4)
0.8
(0.4–1.6)
# M=mutant allels of CYP2D6 i.e. alleles 3, 4 and 5.
* p signiﬁcant < 0.05.As we did not get any previous studies associating hyper-
tension with genotypic variants of CYP2D6, we have this study
to reach a conclusion in this regard.
As regards the genotypic variants of CYP2D6 gene, the
present study showed a signiﬁcantly higher wild genotype 1/1
among hypertensive cases compared to controls with a lower
frequency of mutant genotypes (poor metabolic). This
phenomenon was manifested among cases of subgroups with
obesity that had signiﬁcantly lower mutant homozygous forms
than obese controls and cases with cardiac complications.
Hypertensive cases with diabetes and cases with renal
complication were neglected because their genotyping was
not conﬁrmed. Whereas comparing cases of hypertension
and controls as regards the allelic variants of CYP2D6 gene
showed hypertensive cases exhibited a signiﬁcantly higher fre-
quency for allele 1 than controls.
Actually the impact of CYP2D6 polymorphisms on the clin-
ical outcome of hypertensive drugs had been extensively pub-
lished in several literatures (Arnett et al., 2006; Lefebvre et al.,
2007; Zateyshchikov et al., 2007; Bijl et al., 2009; Goryachkina
et al., 2008; Rau et al., 2009). Depending on which alleles are
present in an individual, a wide range of metabolic activities
was observed among subjects: poor (PM), intermediate (IM),
extensive (EM) and ultrarapid (UM) (Zanger et al., 2004;ne among hypertensive cases compared to controls.
CYP2D6 Alleles
M/M# Allele 1 Allele M
n (%) n (100%) n (%) n (%)
37 (8.6) 858 713(83.1) 145 (61.9)
2 (1.6) 246 226 (91.9) 20 (8.1)
Recessive
M/M vs.
1/1 + 1/M
Allele 1 Allele M
0.008* 0.00097* 0.00097*
0.2
(0.04–0.7)
2.3
(1.4–3.8)
0.4
(0.3–0.7)
ne among obese hypertensive cases compared to controls.
CYP2D6 Alleles
M/M# Allele 1 Allele M
n (%) n (100%) n (%) n (%)
30 (9.5) (636) 525(82.5) 111(17.5)
2 (2.3) 176 160(90.9) 16(9.1)
Recessive
M/M vs.
1/1 + 1/M
Allele 1 vs.
Allele M
Allele M vs.
Allele 1
0.04* 0.007* 0.007*
0.2
(0.05–0.95)
2.1
(1.2–3.7)
0.5
(0.3–0.8)
Table 3 Frequency of genotypic and allelic variants of CYP2D6 gene among cardiac hypertensive cases compared to controls.
CYP2D6 Genotypes CYP2D6 Alleles
1/1 1/M M/M# Allele 1 Allele M
n (%) n (%) n (%) n (100%) n (%) n (%)
Controls n= 429 321 (74.8) 71 (16.6) 37 (8.6) 858 713 (83.1) 145(61.9)
Cardiac Complication n= 76 67 (88.2) 8 (10.5) 1 (1.3) 152 142(93.4) 10(6.6)
Dominant
1/1 vs.
1/M+M/M#
Additive
1/M vs.
1/1 +M/M
Recessive
M/M vs.
1/1 + 1/M
Allele 1 vs.
Allele M
Allele M vs.
Allele 1
p 0.01* 0.2 0.03* 0.002* 0.002*
OR
(95% CI)
2.5
(1.2–5.2)
0.6
(0.3–1.3)
0.1
(0.02–1.05)
2.9
(1.5–5.6)
0.3
(0.2–0.7)
# M=mutant allels of CYP2D6 i.e. alleles 3, 4 and 5.
* p signiﬁcant < 0.05.
232 A.A.A. Ali et al.Kirchheiner et al., 2004; Sistonen et al., 2007; Spina and de
Leon, 2007). PM alleles (e.g.*3,*4,*4 · n,*5,*6,*7,*8,*11 or
*45) cause absent enzymatic activity and, possibly, an increased
risk of adverse drug reactions even with a routine therapy with
CYP2D6 substrates (Marez et al., 1997; Sachse et al., 1998). In
addition, many of the studies have shown that some ethnic
groups have speciﬁc CYP2D6 phenotypes such as CYP2D6*10,
found inAsians andCYP2D6*17, found inAfricans (Bertilsson,
1995; Ma et al., 2002; Evans & Relling, 2004).
On the other hand, the frequency of the phenotype of poor
metabolizers differs among ethnic groups. Less than 1% of
Asians, 2–5% of African–Americans, and 6–10% of Cauca-
sians are poor metabolizers of CYP2D6 (Kalow et al., 1980).
Whereas, the frequencies of CYP2D6*4, allele are described
among different ethnic populations: 20.7% in Caucasians
(Sachse et al., 1997), 7.8% among African Americans (Wan
et al., 2001), 17.84% in Greeks (Arvanitidis et al., 2007),
18.4% in Dutch (Tamminga et al., 2001), 18.2% in Russians
(Gaikovitch et al., 2003), 20.7% in Germans (Sachse et al.,
1997), 15.3% in Italians (Scordo etal., 2004), 33.4% in Faroese
population (Halling et al., 2005), 13.8% in Spanish (Menoyo et
al., 2006), 14% in Croatians (Bozina et al., 2003), 3.5% in the
Saudi population (McLellan et al., 1997) and 2% in the UAE
population (Qumsieh et al., 2011).Conclusion
CYP2D6 polymorphism is positively associated with hyperten-
sive cardiac complications and hypertensive obese cases. Actu-
ally some caution-in the interpretation of the data-is warranted
because of the relatively small number of studied subjects,
especially in subgroup analysis. In this respect, we recommend
a wider scale analysis recruiting a large sample of hypertensive
cases and also involving a wide genome association study to
conﬁrm these results and search for other important interactive
genomic markers.Acknowledgement
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